ArticleCureus2025
The Complexities of Managing Acute Coronary Syndrome in a Patient With Hereditary Hemorrhagic Telangiectasia: A Case Report and Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hereditary hemorrhagic telangiectasia (HHT) is an uncommon autosomal dominant genetic disorder characterized by mucocutaneous and gastrointestinal telangiectasias and visceral arteriovenous malformations (AVMs). Patients with HHT have an increased risk of both bleeding and arterial and venous thrombosis. Due to the increased risk of bleeding, these patients generally cannot tolerate antiplatelet or anticoagulant therapies. This poses a particular hurdle when treating acute coronary syndrome (ACS). Our case involves a 79-year-old male patient with a past medical history of HHT, major gastrointestinal bleeding (GIB), and coronary artery disease who presented with a non-ST-segment elevation myocardial infarction (NSTEMI) and acute-on-chronic anemia. Our treatment options were limited given his intolerance to antiplatelet and anticoagulant therapies which resulted in major GIB, making him a poor candidate for percutaneous coronary intervention. We consulted cardiology and treated him with beta-blockers to decrease oxygen demand, packed red blood cell (PRBC) transfusion to increase oxygen supply, and ranolazine for symptom relief. His symptoms improved and he was discharged. Four weeks later, he suffered a cardiac arrest due to ventricular fibrillation. His family chose to pursue comfort measures, and he was transferred to an inpatient hospice. By reporting this case, we aim to highlight the unique challenges faced when managing ACS in patients with HHT. We underscore the importance of mitigating the risks of coronary artery disease in these patients. Given the limited treatment options and low tolerance to treatment modalities used for ACS, early detection of HHT and implementing effective primary prevention strategies are crucial in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.